FiercePharmaOriginal article
{"a":[{"_":"Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win","$":{"href":"/pharma/roche-gsk-novartis-billion-dollar-deals-more-mfn-sign-ups-akeso-os-win","hreflang":"en"}}]}
Data ReadoutpositiveivonescimabKeytrudaPositive
AI Analysis
Summary
Roche, GSK, and Novartis expanded dealmaking with Asian biopharmas. Akeso and Summit's ivonescimab demonstrated a head-to-head overall survival advantage versus Keytruda in a clinical trial.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
ivonescimab delivered head-to-head overall survival win against Keytruda
Importance:6/10
Sentiment:
0.70
M&Apartnershipclinical dataAsiaoncology
Read the original article
Published by FiercePharma on September 3, 2026 10:34 PM